{"id":12099,"date":"2021-04-27T16:34:28","date_gmt":"2021-04-27T11:04:28","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12099"},"modified":"2021-07-24T12:58:21","modified_gmt":"2021-07-24T07:28:21","slug":"pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure","title":{"rendered":"Ocugen-Bharat Biotech\u2019s Covaxin  Against B.1.617 Corona Variant; uniQure Shares; J&#038;J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e121a6dfa62\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e121a6dfa62\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure\/#Ocugen-Bharat_Biotechs_Covaxin_Shows_Efficacy_Against_B1617_Variant\" >Ocugen-Bharat Biotech\u2019s Covaxin Shows Efficacy Against B.1.617 Variant<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure\/#Why_are_uniQure_Shares_Shooting_Up_Today\" >Why are uniQure Shares Shooting Up Today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure\/#Johnson_Johnson_Vaccine_Back_in_the_Picture_Again\" >Johnson &amp; Johnson Vaccine Back in the Picture Again&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure\/#Sanofi_Shakes_Hands_with_Moderna_to_Make_COVID-19_Vaccines_for_the_US\" >Sanofi Shakes Hands with Moderna to Make COVID-19 Vaccines for the US<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-ocugen-bharat-biotech-s-covaxin-shows-efficacy-against-b-1-617-variant\"><span class=\"ez-toc-section\" id=\"Ocugen-Bharat_Biotechs_Covaxin_Shows_Efficacy_Against_B1617_Variant\"><\/span><strong>Ocugen-Bharat Biotech\u2019s Covaxin Shows Efficacy Against B.1.617 Variant<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With the COVID-19 cases exponentially increasing, there is a worrisome climate all over the world. Physicians, doctors, researchers, the whole healthcare and pharmaceutical industry are at their toes fighting the second wave of the coronavirus infection.&nbsp;<\/p>\n\n\n\n<p>It seems a new strain of the virus-containing 2 mutations E484Q and L452R, variant known as B.1.617, is behind the surge in the cases in <a href=\"https:\/\/www.delveinsight.com\/blog\/covid-19-vaccine-in-india\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">India<\/a>, Australia, Germany, Ireland, Belgium, New Zealand, Singapore, Namibia, the U.K., and the U.S. Amidst the news of rising cases and death toll, the duo of Bharat Biotech and Pennsylvania-based Ocugen released a study giving everyone hope.&nbsp;<\/p>\n\n\n\n<p>Their COVID-19 vaccine, Covaxin, which has already been approved under emergency use authorization from the Indian drug regulator, is now under tests in COVID-19 patients infected with variants B.1.1.7 (n=2), B.1.351(n=2), B.1.1.28.2(n=2), and B1 (n=11). The results showed that the vaccine had the potential to neutralize the B.1.617. The findings are promising and may pave the way for the vaccine to the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/us-healthcare-outlook-report?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">US healthcare market<\/a><\/strong>.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-are-uniqure-shares-shooting-up-today\"><span class=\"ez-toc-section\" id=\"Why_are_uniQure_Shares_Shooting_Up_Today\"><\/span><strong>Why are uniQure Shares Shooting Up Today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>After the USFDA had put a clinical hold on the clinical trial investigating uniQure\u2019s gene therapy for <a href=\"https:\/\/www.delveinsight.com\/blog\/hemophilia-b-market\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Hemophilia B,<\/a> the company began the comprehensive investigation to prove the innocence of its therapy.&nbsp;<\/p>\n\n\n\n<p>During the trials, a patient who had received the investigation gene therapy <strong>AMT-061 <\/strong>in the HOPE-B (NCT03569891) trial was diagnosed with hepatocellular carcinoma (HCC), however, the company announced that the diagnosis was in no way the consequence of gene therapy.&nbsp;<\/p>\n\n\n\n<p>As per the announcement, the patient had multiple risk factors associated with HCC, such as a 25-year history of hepatitis C and hepatitis B, which have been associated with approximately 80% of HCC cases.&nbsp;<\/p>\n\n\n\n<p>Thus, after all the issues were addressed by the company, it was concluded that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">adeno-associated virus (AAV) vector used in the gene therapy<\/a> did not lead to that case of liver cell cancer the FDA gave the company to continue the Hope-B trial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-johnson-johnson-vaccine-back-in-the-picture-again\"><span class=\"ez-toc-section\" id=\"Johnson_Johnson_Vaccine_Back_in_the_Picture_Again\"><\/span><strong>Johnson &amp; Johnson Vaccine Back in the Picture Again&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Finally, the USFDA and CDC have lifted the restriction they had put on Johnson &amp; Johnson <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-therapeutic-pipeline-vaccines?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">COVID-19 vaccine<\/a> announcing that the benefits outweighed the risks.&nbsp;<\/p>\n\n\n\n<p>Owing to the cases of \u201crare and severe\u201d type of blood clot known as cerebral venous sinus thrombosis (CVST) in combination with low levels of blood platelets (thrombocytopenia), the distribution of the vaccine was put on pause.&nbsp;<\/p>\n\n\n\n<p>Initially, the vaccine had an advantage over the other two vaccines namely by Pfizer and Moderna, due to its logistics advantage as it needs not be frozen and requires only one dose. Although, the snags did halt its speedy journey, however, it seems the road is clear now.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-shakes-hands-with-moderna-to-make-covid-19-vaccines-for-the-us\"><span class=\"ez-toc-section\" id=\"Sanofi_Shakes_Hands_with_Moderna_to_Make_COVID-19_Vaccines_for_the_US\"><\/span><strong>Sanofi Shakes Hands with Moderna to Make COVID-19 Vaccines for the US<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As the global demand for the <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-vaccine-candidates\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19 vaccine<\/a> continues, pharmaceutical companies are expanding their manufacturing capacities to accommodate and fulfill the demand. Following the course, Sanofi announced a collaboration with Moderna to bolster the number of&nbsp; authorized vaccines while simultaneously propelling its R&amp;D towards the development of its own preventative medicines.&nbsp;<\/p>\n\n\n\n<p>The tie-up between the companies marks the third such kind of vaccine manufacturing deal Sanofi has struck. The company is already in similar kinds of collaborations with J&amp;J and BioNtech.<\/p>\n\n\n\n<p>A Sanofi plant in Frankfurt, Germany, is set to provide 125 million doses of the Pfizer-BioNTech vaccine that will be supplied to the European Union, while another of its site in France, will produce 12 million doses per month of the Johnson &amp; Johnson COVID-19 vaccine.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ocugen-Bharat Biotech\u2019s Covaxin Shows Efficacy Against B.1.617 Variant With the COVID-19 cases exponentially increasing, there is a worrisome climate all over the world. Physicians, doctors, researchers, the whole healthcare and pharmaceutical industry are at their toes fighting the second wave of the coronavirus infection.&nbsp; It seems a new strain of the virus-containing 2 mutations E484Q [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":12102,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[10830,15648,285,2789,16972,533],"industry":[17225],"therapeutic_areas":[17235,17233,17243],"class_list":["post-12099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-covid-19","tag-covid-19-vaccines","tag-hemophilia-b","tag-jhonson-jhonsons","tag-moderna","tag-sanofi","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-hematological-disorders","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Covaxin Potential; uniQure Shares; J&amp;J Vaccine; Sanofi-Moderna Deal<\/title>\n<meta name=\"description\" content=\"Ocugen-Bharat Biotech\u2019s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&amp;J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covaxin Potential; uniQure Shares; J&amp;J Vaccine; Sanofi-Moderna Deal\" \/>\n<meta property=\"og:description\" content=\"Ocugen-Bharat Biotech\u2019s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&amp;J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-27T11:04:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/27163315\/COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Covaxin Potential; uniQure Shares; J&J Vaccine; Sanofi-Moderna Deal","description":"Ocugen-Bharat Biotech\u2019s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure","og_locale":"en_US","og_type":"article","og_title":"Covaxin Potential; uniQure Shares; J&J Vaccine; Sanofi-Moderna Deal","og_description":"Ocugen-Bharat Biotech\u2019s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-04-27T11:04:28+00:00","article_modified_time":"2021-07-24T07:28:21+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/27163315\/COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure","name":"Covaxin Potential; uniQure Shares; J&J Vaccine; Sanofi-Moderna Deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/27163315\/COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin.png","datePublished":"2021-04-27T11:04:28+00:00","dateModified":"2021-07-24T07:28:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Ocugen-Bharat Biotech\u2019s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ocugen-bharat-jj-sanofi-moderna-uniqure#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/27163315\/COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/27163315\/COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin.png","width":772,"height":482,"caption":"COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/27163315\/COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Covid-19 vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">hemophilia B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Jhonson &amp; Jhonson\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Moderna<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Covid-19 vaccines<\/span>","<span class=\"advgb-post-tax-term\">hemophilia B<\/span>","<span class=\"advgb-post-tax-term\">Jhonson &amp; Jhonson\u2019s<\/span>","<span class=\"advgb-post-tax-term\">Moderna<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 27, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 27, 2021 4:34 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12099"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12099\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12102"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12099"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12099"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}